{"id":"W4200262376","doi":"10.1016/j.clgc.2021.12.003","title":"Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre hospitalier universitaire de Québec; McMaster University; University of Ottawa; Centre Hospitalier de l’Université de Montréal; CancerCare Manitoba; Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; Foothills Medical Centre; University of British Columbia; Juravinski Cancer Centre; Jewish General Hospital; Sunnybrook Health Science Centre; Alberta Cancer Foundation; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Ipilimumab; Nivolumab; Medicine; Discontinuation; Renal cell carcinoma; Internal medicine; Cohort; Oncology; Kidney cancer; Adverse effect; Expanded access; Cancer; Surgery; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003165753,0.000198086,0.0008962628,0.0001456873,0.00002705648,0.000003847556,0.00007324982,0.00009082811,0.0002091776],"category_scores_gemma":[0.0001217177,0.0001789747,0.000197805,0.000443666,0.000183774,0.00005687207,0.0001232852,0.0002335809,0.000002686418],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002972783,"about_ca_system_score_gemma":0.0007370424,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006495464,"about_ca_topic_score_gemma":0.0004148311,"domain_scores_codex":[0.9973756,0.0002762082,0.001257922,0.0004774418,0.0003782887,0.0002345445],"domain_scores_gemma":[0.9983464,0.0003129466,0.0003559228,0.0004353177,0.0003650339,0.0001843289],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002774557,0.001230599,0.9842589,0.0005076739,0.0001220329,0.0003219779,0.0001385415,0.00005611186,0.0005409464,0.000007036935,0.0002620916,0.009779453],"study_design_scores_gemma":[0.009577626,0.001281123,0.97504,0.0002174592,0.0004714035,0.000009515131,0.00008200952,0.0003083897,0.01255487,0.000028923,0.0002971921,0.0001315236],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921693,0.002922449,0.00001187928,0.00007731865,0.0002002281,0.0006516254,0.0000648199,0.00001001228,0.003892342],"genre_scores_gemma":[0.9945049,0.003027885,0.0007790531,0.00006874445,0.00008938957,0.00004343197,0.0001252549,0.00002867636,0.001332689],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01201392,"threshold_uncertainty_score":0.7298378,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07943066627634919,"score_gpt":0.3662064179276324,"score_spread":0.2867757516512832,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}